{
    "root": "357e77bb-7d32-c2e8-e063-6394a90a3427",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Citalopram",
    "value": "20250509",
    "ingredients": [
        {
            "name": "CITALOPRAM HYDROBROMIDE",
            "code": "I1E9D14F36",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3724"
        }
    ],
    "indications": {
        "text": "citalopram tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer daily without food ( 2 ) . \u2022 initial 20 mg daily ; one week may increase maximum 40 mg daily ( 2.1 ) . \u2022 patients greater 60 years age , patients hepatic impairment , cyp2c19 poor metabolizers : maximum recommended 20 mg daily ( 2.2 ) . \u2022 discontinuing citalopram tablets , reduce gradually ( 2.4 , 5.6 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "citalopram tablets , usp contain citalopram hydrobromide usp , equivalent 20 mg citalopram base . citalopram tablets , usp 20 mg bottle 30 ndc 42708-091-30 tan coloured , oval shaped , biconvex film coated tablets \u2018 2\u25020 \u2019 debossed ( \u2018 2 \u2019 left side \u2018 0 \u2019 right side break line ) one side \u2018 1010 \u2019 side . storage handling store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "citalopram tablets contraindicated patients : \u2022 taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . \u2022 taking pimozide risk qt prolongation [ ( 7 ) ] . \u2022 known hypersensitivity citalopram inactive ingredients citalopram tablets . included angioedema anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see Clinical Studies (\n  \n   14)]\n \n  .",
    "contraindications_original": "\u2022 Administer once daily with or without food ( 2 ) . \u2022 Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ) . \u2022 Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily ( 2.2 ) . \u2022 When discontinuing citalopram tablets, reduce dosage gradually ( 2.4 , 5.6 ) .",
    "warningsAndPrecautions_original": "Citalopram Tablets, USP contain citalopram hydrobromide USP, equivalent to 20 mg citalopram base.\n                  Citalopram Tablets, USP 20 mg\n                  Bottle of 30 NDC 42708-091-30\n                  Tan coloured, oval shaped, biconvex film coated tablets with \u20182\u25020\u2019 debossed (\u20182\u2019 on left side and \u20180\u2019 on right side of the break line) on one side and \u20181010\u2019 on the other side.\n                  Storage and Handling\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Citalopram tablets are contraindicated in patients: \n    \u2022 taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome\n \n  [see Warnings and Precautions (\n  \n   5.3), Drug Interactions (\n  \n   7)]\n \n  . \n    \u2022 taking pimozide because of risk of QT prolongation\n \n  [see Drug Interactions (\n  \n   7)]\n \n  . \n    \u2022 with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. Reactions have included angioedema and anaphylaxis\n \n  [see Adverse Reactions (\n  \n   6.2)]\n \n  .",
    "drug": [
        {
            "name": "Citalopram",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3723"
        }
    ]
}